Volume | 45,621 |
|
|||||
News | - | ||||||
Day High | 2.31 | Low High |
|||||
Day Low | 2.12 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.13 | 2.12 | 2.31 | 2.18 | 2.1399 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
208 | 45,621 | $ 2.18 | $ 99,610 | - | 1.7801 - 39.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:44:26 | 1 | $ 2.07 | USD |
Revelation Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.1k | 209.91k | - | 0 | -120k | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Revelation Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.30 | 2.3299 | 2.022 | 2.13 | 28,849 | -0.12 | -5.22% |
1 Month | 2.71 | 2.84 | 1.7801 | 2.26 | 48,003 | -0.53 | -19.56% |
3 Months | 3.12 | 4.34 | 1.7801 | 3.01 | 245,237 | -0.94 | -30.13% |
6 Months | 18.60 | 25.26 | 1.7801 | 7.86 | 273,169 | -16.42 | -88.28% |
1 Year | 35.70 | 39.00 | 1.7801 | 16.04 | 215,496 | -33.52 | -93.89% |
3 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.01 | 1,277,273 | -8,796.82 | -99.98% |
5 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.01 | 1,277,273 | -8,796.82 | -99.98% |
Revelation Biosciences Description
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |